New Study on the Health Economics of Soft Tissue Sarcoma Treatment – STREXIT 2 Project
STREXIT 2 Project shared a post on LinkedIn about a paper by Judit Józwiak-Hagymásy et al. published in Critical Reviews in Oncology/Hematology:
“New Study on the Health Economics of Soft Tissue Sarcoma Treatment
A new scientific article from the Strexit 2 Project – ‘Economic Evaluations and Health Economic Models of Soft Tissue Sarcomas: A Systematic Literature Review from a European and North American Perspective’ – has been published in Critical Reviews in Oncology/Hematology.
The study provides a comprehensive review of existing economic evaluations and health economic models related to soft tissue sarcomas (STS). Researchers, including Winan van Houdt and Alessandro Gronchi, the Primary Investigators of the STREXIT 2 Project, found that while a substantial number of publications exist, they often focus on a narrow patient subgroup—those ineligible for surgery.
Key findings of the study include:
- Most evaluations, especially for pharmaceuticals, use simplified methodologies applied across different jurisdictions.
- Several studies exhibit methodological limitations, such as short time horizons, inappropriate comparator selection, input data bias
- Given these issues, critical evaluation of past publications is essential to improve future economic assessments in this field.”
Authors: Judit Józwiak-Hagymásy, Ábel Széles, Tamás Dóczi, Bertalan Németh, Dóra Mezei, Hédi Varga, Alessandro Gronchi, Winan van Houdt, Attila Tordai, Marcell Csanádi.
More posts featuring STREXIT 2 Project.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023